GlycoMimetics Operating Income 2012-2025 | CBIO
GlycoMimetics operating income from 2012 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
GlycoMimetics Annual Operating Income
(Millions of US $) |
| 2024 |
$-40 |
| 2023 |
$-39 |
| 2022 |
$-47 |
| 2021 |
$-63 |
| 2020 |
$-52 |
| 2019 |
$-61 |
| 2018 |
$-52 |
| 2017 |
$-34 |
| 2016 |
$-32 |
| 2015 |
$-13 |
| 2014 |
$-11 |
| 2013 |
$-11 |
| 2012 |
$4 |
| 2011 |
$-6 |
GlycoMimetics Quarterly Operating Income
(Millions of US $) |
| 2025-03-31 |
$-2 |
| 2024-12-31 |
$-7 |
| 2024-09-30 |
$-11 |
| 2024-06-30 |
$-10 |
| 2024-03-31 |
$-11 |
| 2023-12-31 |
$-10 |
| 2023-09-30 |
$-10 |
| 2023-06-30 |
$-9 |
| 2023-03-31 |
$-11 |
| 2022-12-31 |
$-11 |
| 2022-09-30 |
$-9 |
| 2022-06-30 |
$-13 |
| 2022-03-31 |
$-15 |
| 2021-12-31 |
$-17 |
| 2021-09-30 |
$-17 |
| 2021-06-30 |
$-14 |
| 2021-03-31 |
$-14 |
| 2020-12-31 |
$-16 |
| 2020-09-30 |
$-14 |
| 2020-06-30 |
$-14 |
| 2020-03-31 |
$-8 |
| 2019-12-31 |
$-15 |
| 2019-09-30 |
$-14 |
| 2019-06-30 |
$-17 |
| 2019-03-31 |
$-15 |
| 2018-12-31 |
$-15 |
| 2018-09-30 |
$-13 |
| 2018-06-30 |
$-12 |
| 2018-03-31 |
$-12 |
| 2017-12-31 |
$-10 |
| 2017-09-30 |
$-8 |
| 2017-06-30 |
$-8 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-8 |
| 2016-09-30 |
$-8 |
| 2016-06-30 |
$-8 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-9 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$10 |
| 2015-03-31 |
$-7 |
| 2014-12-31 |
$-7 |
| 2014-09-30 |
$-7 |
| 2014-06-30 |
$8 |
| 2014-03-31 |
$-5 |
| 2013-12-31 |
$-4 |
| 2013-09-30 |
$-4 |
| 2013-06-30 |
$-3 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
